Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Liabilities (2018 - 2025)

Historic Total Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $6.1 million.

  • China SXT Pharmaceuticals' Total Liabilities fell 6166.15% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 6166.15%. This contributed to the annual value of $6.2 million for FY2025, which is 3232.57% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Total Liabilities of $6.1 million as of Q3 2025, which was down 6166.15% from $6.2 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Total Liabilities registered a high of $18.6 million during Q1 2021, and its lowest value of $6.1 million during Q3 2025.
  • For the 5-year period, China SXT Pharmaceuticals' Total Liabilities averaged around $11.4 million, with its median value being $9.4 million (2023).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Total Liabilities skyrocketed by 6781.95% in 2024, and later crashed by 6166.15% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Liabilities (Quarter) stood at $8.9 million in 2021, then fell by 17.87% to $7.3 million in 2022, then skyrocketed by 30.44% to $9.5 million in 2023, then skyrocketed by 67.82% to $16.0 million in 2024, then crashed by 61.66% to $6.1 million in 2025.
  • Its Total Liabilities was $6.1 million in Q3 2025, compared to $6.2 million in Q1 2025 and $16.0 million in Q3 2024.